Manufacture of Healthy and Highly Functioning Gene-Edited Immune Cells

ARE YOU LOOKING TO ENGINEER YOUR CELLS TO MANUFACTURE HEALTHY AND HIGHLY FUNCTIONING IMMUNE CELLS?

Avectas’ team will discuss how the Solupore® delivery platform overcomes challenges in cell engineering and gene-editing existing with conventional methods.

The webinar will also feature the newly launched Solupore® system, the panel will describe how it can support therapeutic partners in achieving a multi-edited highly functional immune cells for their therapeutic needs.

Join us as our panel of experts discuss how Solupore can support therapeutic partners to resolve key manufacturing limitations associated with viral and non-viral cell modification approaches.

WHAT TO EXPECT
Part 1: The panel will address key challenges associated with gene editing and how the Solupore platform can enable the manufacture of next-generation cell therapeutic products including:

• Current manufacturing challenges associated with gene editing of primary cells
• Use of a non-viral transfection platform that enables complex, multi-step editing for next-generation cell therapy products
• Generation of primary edited cells which retain high levels of stem-cell memory with minimal apoptosis
• Enhanced in vitro and in vivo functional response compared with existing transfection technologies

Part 2: The panel answers audience questions with an interactive Q&A.

00:54:00